Bring the potential of ROZLYTREK® to life
ROZLYTREK
offers convenient
once-daily,
oral dosing1
ROZLYTREK offers convenient once-daily, oral dosing1
Table 1: Recommended dosing for paediatric patients > 6 months
*BSA categories and recommended dosing in Table 1 are based on closely matching exposures to a target dose of 300 mg/m2
**To enable dosing increments of 10 mg, capsules prepared as an oral suspension may be used. Refer to the Method of Administration section below and section 6.6.
Paediatric patients > 1 month to ≤ 6 months of age
The recommended dose for paediatric patients > 1 month to ≤ 6 months of age is 250 mg/m2 BSA entrectinib once daily, using capsules prepared as an oral suspension.
Temporary interruption, dose reduction or discontinuation of treatment with ROZLYTREK may help manage adverse reactions1
Dose reduction
Table 2: Dose reduction schedule for adult and paediatric patients
*To enable dosing increments of 10 mg, capsules prepared as an oral suspension may be used. Refer to the Method of administration section below and section 6.6.
**Monday (100 mg), Tuesday (50 mg), Wednesday (100 mg), Thursday (50 mg), Friday (100 mg), Saturday (50 mg), and Sunday (100 mg).
To read the full product information:
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for details on how to report adverse reactions.
Footnotes
ALT, alanine aminotransferase; AR, adverse reaction; AST, aspartate aminotransferase; BSA, body surface area; ms, millisecond; QT, time from the start of the Q wave to the end of the T wave; QTc, the corrected QT interval; SmPC, summary of product characteristics; ULN, upper limit of normal.
References